XNCR Xencor, Inc.
$29.99▲ +2.78%
Healthcare
Other
After hours
$29.76▼ -0.76%
Oct 27, 5:31 PM ET
Volume 2.11M
Avg Volume (10D) 2.13M
Key Metrics & Fundamentals
Market Cap
$2.23B
P/E Ratio
–
Div Yield
0.00%
52W Range
10.38 - 33.60
% vs 50 MA
17.34%
% vs 200 MA
79.33%
RSI-14
71.0
MACD Histogram
+0.5900
Beta (1Y vs SPY)
1.17
Free Cash Flow
-$56.20M
Gross Rev
$51.22M
Gross Profit
$51.22M
EBITDA
-$29.39M
COGS
–
Operating Exp
$88.29M
Operating Income
-$37.07M
EBIT
-$37.07M
Pretax Income
-$21.92M
Net Income
-$21.73M
EPS (Diluted)
-0.29
Price & Volume History
Loading chart…
Recent News
Xencor Sees Upside Potential After 'Exciting' Kidney Cancer Trial Data, RBC Capital Markets Says
MT Newswires · Oct 27, 2026 11:51 AM ET
RBC Raises Price Target on Xencor to $43 From $20, Keeps Outperform, Speculative Risk
MT Newswires · Oct 27, 2026 7:12 AM ET
Xencor (XNCR) Is Up 15.8% What's Changed After Kidney Cancer Trial Update
Simply Wall St. · Oct 26, 2026 6:21 PM ET
Xencor Catapults On 'Unprecedented,' 'Profound' Cancer Data
Investor's Business Daily · Oct 26, 2026 4:13 PM ET
Xencor Picks Phase 3 Dose After XmAb819 Shows 45.5% Response Rate in Kidney Cancer
MarketBeat · Oct 26, 2026 3:02 PM ET
Xencor Soars 31% on Kidney Cancer Trial Data Showing “Impressive Antitumor Activity”
TIKR · Oct 26, 2026 2:55 PM ET
Sector Update: Healthcare Stocks Softer Monday Afternoon
MT Newswires · Oct 26, 2026 2:11 PM ET
Top Midday Gainers
MT Newswires · Oct 26, 2026 1:56 PM ET
Xencor shares jump as kidney cancer drug data support Phase 3 plans
Proactive · Oct 26, 2026 12:08 PM ET
Xencor stock surges on positive cancer drug trial data
Investing.com · Oct 26, 2026 11:21 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See XNCR's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.